Sunday 22 December 2024

The Pharma Letter Podcast — Episode 4 — The state of biotech investing

Biotechnology
Simon Wentworth
1 September 2021
podcast-episode4-1-

More on this story...

Pharmaceutical
Lightstone Ventures raises $375 million fund
14 September 2021
Biotechnology
Healthcare Temperature Check report released by Jefferies
16 November 2021
Pharmaceutical
USA’s R&D tax credit bill moves forward
22 January 2024
Pharmaceutical
Life sciences industry optimism for 2024 and 2025 growth
8 May 2024


More ones to watch >


Today's issue

Neurocrine Biosciences launches Crenessity in USA
Pharmaceutical
Neurocrine Biosciences launches Crenessity in USA
20 December 2024
Biotechnology
Epitopea teams up with Genevant in $124 million deal
20 December 2024
Biotechnology
Mixed results for GSK’s Zejula/Jemperli combo
20 December 2024
Biotechnology
Regeneron advances anticoagulant antibody program
20 December 2024
Pharmaceutical
Zealand blindsided by FDA rejection of glepaglutide
20 December 2024
Biotechnology
Astellas partners with Sangamo on cutting-edge gene therapy
20 December 2024
Biotechnology
Novartis to shut MorphSys sites amid pelabresib delay
20 December 2024

Company Spotlight

Australian regenerative medicine company Mesoblast (ASX: MSB) is developing biotherapeutics based on its proprietary cell-based technologies.




More Features in Biotechnology

Epitopea teams up with Genevant in $124 million deal
20 December 2024
Mixed results for GSK’s Zejula/Jemperli combo
20 December 2024
Regeneron advances anticoagulant antibody program
20 December 2024
Astellas partners with Sangamo on cutting-edge gene therapy
20 December 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze